Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis

Article Abstract:

The presence of the protein anti-Ro52 in patients with systemic sclerosis (SSc) may be a marker for Sjogren's syndrome. This syndrome, characterized by dry eyes and mouth, is an auto-immune disease previously associated with a complex of anti-Ro/SS-A antibodies. Blood samples taken from 27 patients with SSc that were positive for this complex were tested for the presence of the two component proteins, anti-Ro52 and anti-Ro60. Sjogren's syndrome was strongly associated with the presence of both proteins or with anti-Ro52 alone, but only one of the six patients with only anti-Ro60 had symptoms.

Author: Fujimoto, M., Kikuchi, K., Sato, S., Ihn, H., Tamaki, T., Tamaki, K., Shimozuma, M., Yazawa, N., Kubo, M.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1997
Health aspects, Autoantibodies, Sjogren's syndrome

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Antiubiquitin antibody in localised and systemic scleroderma

Article Abstract:

An antibody reactive to ubiquitin may play a role in localized scleroderma and systemic sclerosis. Ubiquitin is a common protein component of cell membranes. Localized scleroderma and systemic sclerosis are autoimmune diseases. Analysis of blood samples revealed positive antibody levels in 21 of 48 localized scleroderma patients and 22 of 52 systemic sclerosis patients. By comparison, levels were positive in 13 of 20 systemic lupus erythematosus patients, 2 of 20 dermatomyositis patients and none of 30 healthy volunteers.

Author: Fujimoto, M., Takehara, K., Sato, S., Ihn, H., Kihkuchi, K., Tamaki, T., Tamaki, K.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 1996
Ubiquitin

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Serum concentrations of soluble P-selectin glycoprotein ligand-1 are increased in patients with systemic sclerosis: Association with lower frequency of pulmonary fibrosis

Article Abstract:

Systemic sclerosis is an autoimmune disorder due to antinuclear antibodies present. Serum concentrations of soluble P-selectin glycoprotein ligand-1 are used in patients with systemic sclerosis and the results are discussed.

Author: Yanaba, K., Takehara, K., Sato, S.
Publisher: British Medical Association
Publication Name: Annals of the Rheumatic Diseases
Subject: Health
ISSN: 0003-4967
Year: 2004
United States, Science & research, Research, Glycoproteins, Pulmonary fibrosis, Sclerosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Diagnosis, Physiological aspects, Systemic scleroderma, Scleroderma (Disease)
Similar abstracts:
  • Abstracts: Increased levels of serum IgM antibody to staphylococcal enterotoxin B in patients with rheumatoid arthritis. Cytokine production by endothelial cells infected with human T cell lymphotropic virus type I
  • Abstracts: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
  • Abstracts: HIV pathogenesis and treatment strategies. Survival in 2367 zidovudine-treated patients according to use of other nucleoside drugs
  • Abstracts: Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support
  • Abstracts: Geriatric medicine. A randomized, controlled trial of a geriatric assessment unit in a community rehabilitation hospital
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.